Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q7Z4H3

UPID:
HDDC2_HUMAN

ALTERNATIVE NAMES:
HD domain-containing protein 2; Hepatitis C virus NS5A-transactivated protein 2

ALTERNATIVE UPACC:
Q7Z4H3; Q5TDQ4; Q6NZ49; Q9BTT2; Q9BV31; Q9Y3D1

BACKGROUND:
The enzyme 5'-deoxynucleotidase HDDC2, with alternative names HD domain-containing protein 2 and Hepatitis C virus NS5A-transactivated protein 2, is integral to the dephosphorylation of dAMP, dCMP, dGMP, and dTMP. This activity is vital for maintaining nucleotide homeostasis, influencing DNA synthesis and maintenance.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionality of 5'-deoxynucleotidase HDDC2 offers a promising avenue for developing novel therapeutic approaches. Given its central role in nucleotide metabolism, targeting HDDC2 could provide innovative treatments for conditions related to aberrant DNA replication and repair.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.